Introduction
Diarrhoea-predominant irritable bowel syndrome (IBS-D) is a common subtype of disorders of gut–brain interaction, characterized by chronic abdominal pain associated with altered bowel habits, predominantly loose or frequent stools. IBS affects a substantial proportion of the global population, with IBS-D representing a clinically challenging subtype due to urgency, stool inconsistency, and impaired quality of life. Current pharmacological options, including antispasmodics, loperamide, bile acid modulators, and neuromodulators, often provide incomplete relief and may be associated with adverse effects or symptom relapse. This therapeutic gap has driven increasing interest in plant-based and traditional medicinal systems, including Ayurveda.1
Pathophysiological rationale for Ayurvedic interventions
IBS-D is understood to involve dysregulation of the gut–brain axis, visceral hypersensitivity, altered intestinal motility, immune activation, and gut microbiota imbalance. Ayurvedic medicine conceptualizes similar dysfunction through derangements of pitta and vata doshas, along with impaired digestive capacity (agni) and accumulation of toxic metabolic by-products (ama). These concepts, although traditional in origin, conceptually align with modern understandings of dysbiosis, low-grade inflammation, and abnormal gastrointestinal motility. Consequently, Ayurvedic herbs are proposed to exert therapeutic effects through multi-target modulation of gastrointestinal function, inflammation, and microbial balance.
Common Ayurvedic herbs investigated in IBS-D
- Recent clinical and experimental studies have evaluated several Ayurvedic botanicals and polyherbal formulations in IBS-D. Among the most studied are Curcuma longa (turmeric), Terminalia chebula, Emblica officinalis, and Murraya koenigii, often used in combination formulations such as traditional decoctions or standardized extracts.
- Curcumin, the principal bioactive compound in turmeric, has demonstrated anti-inflammatory and antioxidant properties by downregulating pro-inflammatory cytokines (e.g., TNF-α, IL-6) and modulating serotonergic signaling pathways involved in gut motility. Experimental data also suggest its role in restoring intestinal barrier integrity and influencing gut microbiota composition. Triphala, a classical Ayurvedic formulation comprising Terminalia chebula, Terminalia bellirica, and Emblica officinalis, has shown prebiotic effects, enhancement of microbial diversity, and mild regulatory effects on bowel motility, making it relevant in IBS-D where dysbiosis is commonly implicated.
- Other Ayurvedic herbs, including Aegle marmelos and Piper longum, have demonstrated antidiarrheal and spasmolytic properties in preclinical models, potentially via modulation of intestinal smooth muscle contractility and calcium channel activity. These multi-component effects support their theoretical utility in reducing stool frequency and improving stool consistency in IBS-D.2
Clinical evidence for efficacy
Clinical studies assessing Ayurvedic interventions in IBS-D remain limited but suggest variable efficacy. A randomized crossover trial evaluating a combined Ayurvedic formulation containing turmeric, curry leaf, and pomegranate reported no statistically significant superiority over placebo in improving IBS symptom severity, although the intervention was well tolerated. Other smaller trials and observational studies have reported modest improvements in abdominal pain, stool frequency, and global symptom scores, particularly when polyherbal preparations are used over short durations.
Systematic reviews of plant-based therapies in IBS indicate that while peppermint oil and certain standardized botanical extracts demonstrate consistent benefits, evidence supporting Ayurvedic multi-herb formulations remains heterogeneous, with significant variability in study design, dosing, and outcome measures. Overall, current clinical evidence suggests potential symptomatic benefit in IBS-D, but not definitive disease-modifying efficacy.
Safety profile and tolerability
- Most Ayurvedic herbs studied in IBS-D appear to have a favorable safety profile when used in standardized doses over short durations. Reported adverse effects are generally mild and include gastrointestinal discomfort, nausea, or transient bloating. Curcumin and Triphala are generally well tolerated, though high doses may occasionally lead to loose stools or abdominal cramping. Importantly, variability in preparation quality, lack of standardization, and potential contamination in non-regulated products remain key safety concerns in real-world use.
- Drug–herb interactions are another consideration, particularly in patients receiving antidiarrheals, antispasmodics, or psychotropic medications for IBS-related symptoms. However, serious adverse events in clinical studies are rare.3
Conclusion and future directions
Ayurvedic herbs demonstrate promising multi-target effects relevant to the pathophysiology of IBS-D, including modulation of gut motility, inflammation, and microbiota composition. However, current clinical evidence remains preliminary and inconsistent. While safety profiles appear acceptable, robust large-scale randomized controlled trials are required to establish efficacy, standardize formulations, and evaluate long-term outcomes. Integration of Ayurvedic principles with modern clinical research methodologies may provide a more comprehensive therapeutic strategy for IBS-D management in the future.
References:
- Altomare A, Di Rosa C, Imperia E, Emerenziani S, Cicala M, Guarino MPL. Diarrhea Predominant-Irritable Bowel Syndrome (IBS-D): Effects of Different Nutritional Patterns on Intestinal Dysbiosis and Symptoms. Nutrients. 2021;13(5):1506. Published 2021 Apr 29. doi:10.3390/nu13051506 https://pmc.ncbi.nlm.nih.gov/articles/PMC8146452/
- Lauche R, Kumar S, Hallmann J, et al. Efficacy and safety of Ayurvedic herbs in diarrhoea-predominant irritable bowel syndrome: A randomised controlled crossover trial. Complement Ther Med. 2016;26:171-177. doi:10.1016/j.ctim.2016.04.002 https://www.sciencedirect.com/science/article/abs/pii/S0965229916300528
- Naik TD, Tubaki BR, Patankar DS. Efficacy of whole system ayurveda protocol in irritable bowel syndrome - A Randomized controlled clinical trial. J Ayurveda Integr Med. 2023;14(1):100592. doi:10.1016/j.jaim.2022.100592 https://pmc.ncbi.nlm.nih.gov/articles/PMC10105243/